710022

antibody from Invitrogen Antibodies

Targeting: BMP2 BMP2A

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

710022

Provider

Invitrogen Antibodies

Product name

BMP-2 Recombinant Polyclonal Antibody (18HCLC)

Antibody type

Polyclonal

Antigen

Other

Reactivity

Human

Host

Rabbit

Isotype

IgG

Antibody clone number

18HCLC

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis.

Carracedo M, Pawelzik SC, Artiach G, Pouwer MG, Plunde O, Saliba-Gustafsson P, Ehrenborg E, Eriksson P, Pieterman E, Stenke L, Princen HMG, Franco-Cereceda A, Bäck M
British journal of pharmacology 2022 Oct;179(19):4709-4721

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of BMP-2 was done on 70% confluent log phase MCF7 cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with BMP-2 (18HCLC), Recombinant Rabbit Polyclonal Antibody (Product # 710022) at 1 µg/mL in 1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing Cytoplasmic localization. Panel e is a no primary antibody control. The images were captured at 60X magnification.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

2 FIGURE Effects of nilotinib on human valvular interstitial cells. (a) Quantification of phosphate-induced calcification of human valvular interstitial cells (VICs) after 9 days. (b) mRNA expression of the osteogenic transcription factor RUNx-2 in VICs treated for 24 h. (c) Immunoblotting against BMP-2 in human VICs after 24 h treatment with control (DMSO), nilotinib (10 muM), or imatinib (10 muM). (d) Immunoblotting against LC3-I and LC3-II in human VICs treated for 2 h with or without bafilomycin (100 nM) followed by 24 h with control (DMSO), nilotinib (10 muM), or imatinib (10 muM). (e) VIC viability after inhibition of autophagy with bafilomycin (B+) (100 nM) or vehicle control (B-) (DMSO) for 2 h, followed by treatment with control (DMSO), nilotinib (10 muM) or imatinib (10 muM) for 24 h. Data are represented as mean +- S.D. Statistical significance of differences between groups were determined when at least n = 5 (d and e). * P < 0.05 Student's t test. Each dot represents one patient VIC donor